Therapeutic hub
Oncology-Related Peptides
Peptide receptor radionuclide therapy, hormone-axis suppression, and peptide-drug conjugates — high-stakes clinical medicine with strict oversight.
Regulatory picture
Approved specialist therapies plus a broad investigational pipeline.
What this area covers
Peptides are used in oncology as targeting vehicles (delivering radionuclides or cytotoxic payloads to receptor-expressing tumours) and as hormone-axis modulators in hormone-sensitive cancers.
These are specialist therapies delivered in controlled clinical settings with defined eligibility criteria and imaging-based patient selection.
Fig. 02 / Molecular pathwayWhy this area is not comparable to consumer peptides
Oncology peptide therapy involves careful dosimetry, multidisciplinary oversight, and significant toxicity management. Nothing in this field supports general-purpose peptide use, and tumour-targeting mechanisms do not imply preventive benefit.
Editorial disclaimer
This site is educational and does not provide medical advice, dosing protocols, or treatment recommendations. Regulatory status and evidence strength differ sharply between compounds. A “research use only” label does not indicate that a product is appropriate for human use. Decisions about medicines belong with a qualified clinician.